UCB SA (UCB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, UCB SA (UCB) has a cash flow conversion efficiency ratio of 0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.52 Billion) by net assets (€10.87 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
UCB SA - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how UCB SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
UCB SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UCB SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OSRAM LICHT N
HM:OSR
|
0.045x |
|
Alimentation Couchen Tard Inc A
TO:ATD
|
0.078x |
|
E.ON SE
F:EOAN
|
0.141x |
|
NATWEST GR.PLC LS 10769
F:RYSD
|
N/A |
|
Loblaw Companies Limited
TO:L
|
0.186x |
|
Mercedes-Benz Group AG
F:MBG
|
0.048x |
|
Ferguson Plc
NYSE:FERG
|
0.071x |
|
L3Harris Technologies Inc
NYSE:LHX
|
0.028x |
Annual Cash Flow Conversion Efficiency for UCB SA (2000–2025)
The table below shows the annual cash flow conversion efficiency of UCB SA from 2000 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €10.87 Billion | €2.16 Billion | 0.199x | +60.72% |
| 2024-12-31 | €10.03 Billion | €1.24 Billion | 0.124x | +46.05% |
| 2023-12-31 | €8.97 Billion | €761.00 Million | 0.085x | -31.32% |
| 2022-12-31 | €9.06 Billion | €1.12 Billion | 0.123x | -33.34% |
| 2021-12-31 | €8.39 Billion | €1.55 Billion | 0.185x | +24.58% |
| 2020-12-31 | €7.27 Billion | €1.08 Billion | 0.149x | +18.13% |
| 2019-12-31 | €7.01 Billion | €882.00 Million | 0.126x | -27.72% |
| 2018-12-31 | €6.25 Billion | €1.09 Billion | 0.174x | +7.73% |
| 2017-12-31 | €5.74 Billion | €927.00 Million | 0.162x | +107.29% |
| 2016-12-31 | €5.48 Billion | €427.00 Million | 0.078x | +75.76% |
| 2015-12-31 | €5.55 Billion | €246.00 Million | 0.044x | -60.71% |
| 2014-12-31 | €4.89 Billion | €552.00 Million | 0.113x | +69.44% |
| 2013-12-31 | €4.32 Billion | €288.00 Million | 0.067x | -13.81% |
| 2012-12-31 | €4.59 Billion | €355.00 Million | 0.077x | +27.66% |
| 2011-12-31 | €4.82 Billion | €292.00 Million | 0.061x | -45.06% |
| 2010-12-31 | €4.59 Billion | €506.00 Million | 0.110x | +64.99% |
| 2009-12-31 | €4.42 Billion | €295.00 Million | 0.067x | -26.70% |
| 2008-12-31 | €4.02 Billion | €366.00 Million | 0.091x | -20.71% |
| 2007-12-31 | €4.26 Billion | €490.00 Million | 0.115x | +71.05% |
| 2006-12-31 | €4.78 Billion | €321.00 Million | 0.067x | -44.19% |
| 2005-12-31 | €2.41 Billion | €290.00 Million | 0.120x | -67.06% |
| 2004-12-31 | €1.96 Billion | €718.17 Million | 0.365x | -3.84% |
| 2003-12-31 | €1.78 Billion | €677.97 Million | 0.380x | -0.34% |
| 2002-12-31 | €1.57 Billion | €596.97 Million | 0.381x | +11.99% |
| 2001-12-31 | €1.39 Billion | €473.45 Million | 0.341x | +18.59% |
| 2000-12-31 | €1.21 Billion | €346.26 Million | 0.287x | -- |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more